WebIn the dose-expansion phase, patients received FCN-411 at the recommended phase II dose (RP2D) continuously in 21-day cycles. The primary endpoints were safety, tolerability, MTD, and RP2D. RESULTS. From July 23, 2024 to September 29, 2024, 77 patients were enrolled, including 30 with EGFR T790M mutation in tumor tissues. The cut-off date was ...
FCN-437 - Fochon Pharmaceuticals Corporation
WebFeb 3, 2024 · In the dose-expansion phase, patients received FCN-411 at the recommended phase II dose (RP2D) continuously in 21-day cycles. The primary endpoints were safety, tolerability, MTD, and RP2D. Results From July 23, 2024 to September 29, 2024, 77 patients were enrolled, including 30 with EGFR T790M mutation in tumor tissues. The … WebFCN 411, a pan-tyrosine kinase (pan-HER) inhibitor, is being developed by Shanghai Fosun Pharmaceutical for the treatment of advanced cancer including non-small s2tw region add workshop
Lung Cancer Trial in Beijing (FCN-411 Dose-escalation, FCN-411 …
WebFCN-437 is a novel, proprietary and orally active inhibitor of Cyclin Dependent Kinase 4 and 6 (CDK4/6). It is being developed by Fochon as a monotherapy and in combination to treat solid tumor. FCN-437 demonstrated much higher in vitro and in vivo potency and selective inhibitory activities against CDK4/6 compared to approved CDK4/6 inhibitors. WebFCN-411. FCN-411 is a novel, proprietary and highly potent pan-HER inhibitor developed by Fochon for the treatment of metastatic NSCLC and HSNCC. Members of the epidermal … WebLF411CN-ND. Manufacturer. Texas Instruments. Manufacturer Product Number. LF411CN. Description. IC OPAMP JFET 1 CIRCUIT 8DIP. Detailed Description. J-FET Amplifier 1 … is fruit juice worse than soda